A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques  by Raviprakash, Kanakatte et al.
6) 166–173
www.elsevier.com/locate/yviroVirology 353 (200A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody
to all four virus serotypes in rhesus macaques
Kanakatte Raviprakash a,⁎, Doris Apt b, Alice Brinkman b, Craig Skinner b, Shumin Yang b,
Glenn Dawes b, Dan Ewing a, Shuenn-Jue Wu a, Steve Bass b, Juha Punnonen b, Kevin Porter a
a Viral Diseases Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
b Maxygen Inc., 515 Galveston Drive, Redwood City, CA 94063, USA
Received 15 March 2006; returned to author for revision 10 April 2006; accepted 1 May 2006
Available online 30 June 2006Abstract
DNA shuffling and screening technologies were used to produce chimeric DNA constructs expressing antigens that shared epitopes from all
four dengue serotypes. Three shuffled constructs (sA, sB and sC) were evaluated in the rhesus macaque model. Constructs sA and sC expressed
pre-membrane and envelope genes, whereas construct sB expressed only the ectodomain of envelope protein. Five of six, and four of six animals
vaccinated with sA and sC, respectively, developed antibodies that neutralized all 4 dengue serotypes in vitro. Four of six animals vaccinated with
construct sB developed neutralizing antibodies against 3 serotypes (den-1, -2 and -3). When challenged with live dengue-1 or dengue-2 virus,
partial protection against dengue-1 was observed. These results demonstrate the utility of DNA shuffling as an attractive tool to create tetravalent
chimeric dengue DNA vaccine constructs, as well as a need to find ways to improve the immune responses elicited by DNA vaccines in general.
Published by Elsevier Inc.Keywords: Dengue vaccines; Chimeric vaccines; DNA vaccinesIntroduction
Dengue is one of the most important arboviral diseases of
humans. An estimated 100 million dengue infections are caused
each year by four antigenically distinct serotypes of dengue
viruses (dengue-1 to dengue-4), resulting in widespread dengue
fever (DF) and at least 250,000 cases of dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) (Halstead, 1988).
These viruses are transmitted primarily by the mosquito Aedes
aegypti and are endemic throughout the tropical and subtropical
regions of the world. A major expansion of dengue transmission
has occurred throughout the tropical Americas accompanied by
a large increase in the number of DHF cases. Despite the public
health importance of DF and DHF, vector control, which has
proven difficult and costly to sustain over time, is the only
available control measure (Gubler, 1994). Vaccines are
available for two related flaviviruses, yellow fever (YF) virus
and Japanese encephalitis (JE) virus (Barrett, 1997a, 1997b).⁎ Corresponding author. Fax: +1 301 319 7451.
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doi:10.1016/j.virol.2006.05.005However, decades of effort have not produced a successful
dengue virus vaccine. A major obstacle to dengue vaccine
development is the epidemiological observation that a dengue
virus infection only produces protective immunity against the
infecting serotype, and that a secondary infection by a
heterologous serotype increases the risk for DHF/DSS. It is
postulated that this increased risk for severe dengue disease
during secondary infections is due to antibody mediated
enhancement (ADE) of infection (Halstead and O'Rourke,
1977), in which virus–antibody complex formed due to pre-
existing antibodies from the primary infection gain greater
access to target cells via the Fc-receptors. It is therefore
imperative that a dengue vaccine produces robust protective
immune responses to all 4 dengue serotypes. Conventional
methodologies such as live attenuated virus vaccines (Edelman et
al., 1994), inactivated dengue viruses (Schlesinger, 1977) and
subunit vaccines (Deubel et al., 1988; Eckels et al., 1994) have
not yet produced a vaccine. More recently, considerable advances
have been made using dengue–yellow fever virus chimeras as
vaccine candidates (Guirakhoo et al., 2001, 2002, 2004).
However, these methodologies have relied on developing 4
Fig. 1. Space filling models depicting the chimeric nature of the deduced amino
acid sequences expressed from shuffled DNA vaccines sA, sB and sC. (A) The
hydrophilic face of the soluble dimeric ectodomain from dengue type 2 is
shown. The dimer is formed by two anti-parallel E monomers, shown in light
gray and dark gray. The 3 domains (I, II and III) of the ectoprotein are outlined.
(B) The hydrophilic face of the shuffled E antigens, where amino acid residues
from dengue-1 dengue-2, dengue-3 and dengue-4 are shown in magenta, tan,
green and blue, respectively. This figure was created with protein explorer
(Martz, 2002) using the atomic coordinates 1OAN (Modis et al., 2003) from the
protein data bank.
167K. Raviprakash et al. / Virology 353 (2006) 166–173individual vaccines, one for each serotype, and mixing them to
produce the final tetravalent formulation. This approach
presents challenges related to commercial scale manufacture
and formulation of a human dengue vaccine.
DNA vaccines offer an alternative strategy for developing
effective dengue virus vaccines. This approach, in which
plasmid DNA expressing an antigen of interest is used as a
vaccine, has been shown to induce immune responses in animal
models against a number of different viruses, including several
flaviviruses (Colombage et al., 1998; Konishi et al., 1998;
Phillpotts et al., 1996; Schmaljohn et al., 1997). A West Nile
virus (also a flavivirus) DNA vaccine has recently been
approved for use in horses (http://www.aphis.usda.gov/lpa/
issues/issues_archive/wnv/wnv_vaccine.html), making it the
first DNA vaccine to be commercially marketed. We have
previously demonstrated the feasibility of DNA vaccines for
dengue viruses in a number of studies (Kochel et al., 1997,
2000; Porter et al., 1998; Raviprakash et al., 1995, 2000a,
2000b, 2001, 2003).
In an effort to produce a single DNA vaccine capable of
eliciting immune responses to all 4 serotypes, we employed
directed molecular evolution by DNA shuffling and screening
to generate chimeric vaccine constructs encoding antigens
comprising epitopes from all four dengue serotypes. DNA
shuffling and screening technologies have previously been used
in evolving interferon-α, IL-12, co-stimulatory molecules and
viruses (Chang et al., 1999; Lazetic et al., 2002; Leong et al.,
2003; Patten et al., 1997; Soong et al., 2000). Using this
approach, we generated a number of chimeric DNA vaccines
that were shown to contain sequences representative of all 4
dengue serotypes. A number of these chimeric DNA vaccines
also produced multivalent neutralizing antibodies in mice and
provided protection against intracerebral challenge by dengue-2
virus (Apt et al., 2005). In the present study, we show that 3
selected chimeric DNA vaccines produced by DNA shuffling
and screening elicited multivalent dengue virus neutralizing
antibodies in vaccinated rhesus macaques. When vaccinated




The DNA shuffling and screening methods used to
generate and select vaccine candidates that expressed antigens
with combined attributes of all four dengue serotypes were
recently described (Apt et al., 2005). Based on murine
immunogenicity studies (Apt et al., 2005), 3 shuffled clones
were selected for evaluation in a nonhuman primate model.
The 3 shuffled clones, 6E12-D4, 18H6 and 2G11-D4
(referred to in this study as sA, sB and sC, respectively),
all expressed antigens that reacted with all 4 dengue-specific
antibodies and elicited antibodies in vaccinated mice that
neutralized all 4 dengue serotypes in vitro (Apt et al., 2005).
The distribution of amino acid sequences from all 4 dengue
serotypes on the hydrophilic surface of each of the 3 shuffledE (envelope) antigens (sA, sB and sC) in a modeled dimer
formation (Modis et al., 2003) is shown in Fig. 1.
Immunogenicity in rhesus macaques
Animals were vaccinated by intramuscular injection of 5 mg
empty vector DNA , shuffled DNA vaccine sA, sB or sC, a
mixture of 1.25 mg each of the 4 wild-type parental DNA (wt-
mix) or a mixture of 1.65 mg each of sA, sB and sC DNA
(sABC) on days 0, 28 (week 4) and 84 (week 12). Treatment
groups and the immunization regimen are shown in Fig. 2. Sera
obtained 4 weeks after the first vaccination were diluted 100-
fold and dengue-specific IgG antibody was measured by
ELISA. All animals (6/6) vaccinated with the wild-type vaccine
mixture (wt-mix) had seroconverted after the first dose and
elicited antibodies that reacted with all 4 dengue antigens (Fig.
3A). Similarly, a majority of animals vaccinated with sA (4/6),
sC (3/6) or sABC (4/6) had seroconverted after first dose
producing antibodies reacting to all 4 dengue antigens;
remaining animals produced antibodies that reacted with 2 or
3 dengue antigens. Vaccine sB produced the lowest antibody
levels after the initial dose, and the antibodies reacted primarily
Fig. 2. Study design. (A) Distribution of animals for vaccination and challenge.
n = number of animals. (B) Vaccination and challenge schedule.
Fig. 3. ELISA reactive antibodies after 1st and 3rd dose of vaccine. Sera were
diluted 1:100 (A) or 1:1000 (B) and dengue-specific IgG reacting with each
serotype antigen was measured by ELISA (week 4 sera were barely positive at
1:1000 dilution). Mean optical density (405 nm) and standard error for each
group against each antigen is shown. All animals were included in the analysis.
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vaccinations, all animals except for the control group produced
antibodies reacting with all 4 dengue antigens. Fig. 3B shows
mean ELISA optical densities for each group for each dengue
antigen, 4 weeks after the last immunization (week 16),
measured at 1:1000 serum dilution.
The ability of these antibodies to neutralize virus in vitro
was measured by plaque reduction neutralization test (PRNT).
All vaccines, except sB, elicited antibodies in a subset of
animals (4/6, 5/6, 4/6, 6/6 for wt-mix, sA, sC and sABC,
respectively) that neutralized all 4 dengue serotypes in vitro.
The geometric mean titers (GMT) for 50% neutralization
(PRNT50) for all vaccines (day 112 sera) against all 4 dengue
serotypes were significantly higher compared to those for the
vector control group (P < 0.05), with the exception of vaccine
sB which elicited antibodies that only neutralized dengue-1,
-2 and -3 (Fig. 4). An examination of the neutralization titers
also revealed that among the 3 individual shuffled vaccines,
vaccine sA performed the best, eliciting mean titers of 27, 23,
58 and 30 against dengue-1, -2, -3 and -4, respectively.
However, by day 224 (day of virus challenge), the GMTs for
all groups against all dengue serotypes had declined by 50%
or more (Fig. 4).
Live virus challenge
Three animals from each group were challenged with live
virus by subcutaneous inoculation of 105 plaque forming units
(PFU) of dengue-1 (strain western pacific 74) or dengue-2
(strain OBS-8041) virus. The vector control group for dengue-1
challenge had 2 animals (1 animal died before the beginning ofthe protocol due to study unrelated cause). Viremia was
assessed by detection of virus in the serum samples of daily
bleeds following virus challenge. Table 1 shows a summary of
viremia data, as well as neutralizing antibody titers at the time of
challenge. Results suggest a partial protection against dengue-1
viremia in vaccinated groups compared to the control group.
The mean days of viremia were reduced from 4 (control group)
to 1.3, 2.3, 1.3, 2.3 and 0.6 for wt-mix, sA, sB, sC and sABC
vaccinated groups, respectively. The reduction in the days of
viremia for the sABC group was statistically significant
(P < 0.05). However, none of the vaccinated groups showed
any reduction in dengue-2 viremia. The neutralizing antibody
levels at the time of challenge had declined from their observed
peak levels at day 112 (Table 1 and Fig. 4), and a clear
correlation between neutralizing antibody titers and protection
from viremia could not be established.
To determine if the vaccination had primed the animals
sufficiently to mount a secondary antibody response to virus
challenge, IgM and IgG antibodies were measured by ELISA
during the challenge phase (Fig. 5). For dengue-1, the vector
control group exhibited a typical primary antibody response in
which there was an initial IgM response by day 6 followed by an
increasing IgG response by day 10 after challenge. The wt-mix,
sB and sC vaccinated animals also showed an IgM response,
although their IgGs were boosted at the same time. sA and
Fig. 4. Virus neutralizing antibodies. Sera from each animal obtained on day 112
(4 weeks after 3rd dose) and on day 224 (day of virus challenge) were used to
measure neutralization of dengue-1, -2, -3 and -4 virus by PRNT. A pre-immune
serum pool of all the animals was used as the base line. GMT of (PRNT50) for
each vaccine group for each dengue serotype is shown.
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antibody response in which their IgG antibodies increased soon
after challenge without significant accumulation of IgM
antibodies. Response to dengue-2 challenge was slower; by
day 10, IgM antibody was still increasing with little
accumulation of IgG antibody in the vector control group.
Anti-dengue2 IgM antibody was still rising on day 10 for sB
vaccinated animals as well, but unlike vector control group,
dengue2-IgG increased simultaneously. Although dengue2-IgG
levels at the time of challenge were substantially lower
compared to dengue-1 IgG, there was a rapid increase in IgG
levels by day 6 without IgM accumulation in wt-mix, sA, sC
and sABC vaccinated animals. Measurement of neutralizing
antibodies on day 10 after challenge clearly showed a slow
primary response for both dengue-1 and dengue-2 challenge in
control animals whereas all vaccinated animals exhibited
significantly high titers indicating an anamnestic antibody
response (Table 2).
Discussion
Development of a dengue vaccine has been complicated by
the need to raise protective immune responses against all 4
dengue serotypes. Traditional approaches that depend on using4 individual dengue virus vaccines mixed to produce a final
vaccine have been plagued by constraints of commercial scale
manufacture and formulation. In this study, we have taken
advantage of the DNA shuffling and screening technology to
produce single DNA vaccine candidates that express antigens
containing immunogenic epitopes from all 4 dengue serotypes.
DNA shuffling and screening is a powerful technology that
allows for the selection of clones based on functional attributes
in the absence of precise information on the location or structure
of the key epitopes. Three shuffled vaccine constructs were
chosen for this study based on previous in vitro characterization
and in vivo data in a murine model (Apt et al., 2005). All 3
chimeras elicited antibodies in mice that neutralized all 4
dengue serotypes in vitro.
This study demonstrated that single shuffled DNA vaccines
sA and sC are capable of producing multiple serotype reactive
antibodies in rhesus macaques. The mixture of 4 parental
monovalent vaccine constructs and the mixture of the shuffled
chimeras also produced antibodies for all serotypes. A tendency
for higher antibody response for dengue-3 and dengue-4
compared to dengue-1 and dengue-2 in all vaccinated groups
including the wt-mix (Figs. 3 and 4) may indicate inherent
differences in the immunogenicity of these E proteins. Shuffled
vaccines sA and sC induced neutralizing antibody titers that
were comparable to those induced by the vaccine mixtures and
caused a reduction in dengue-1 viremia indicating the feasibility
of generating multivalent immune responses by single chimeric
antigens in macaques. However, the best protection against
dengue-1 viremia was demonstrated by the mixture of shuffled
vaccines (sABC) and the mixture of parental DNAvaccines (wt-
mix). No reduction in viremia was observed in vaccinated
animals challenged with dengue-2 virus. It should be noted that
the dengue-1 and dengue-2 sequences used for shuffling were
derived from published envelope protein sequences of strains
AHF 82-80 and D2-04, respectively (Apt et al., 2005). A
comparison of E protein sequences of AHF 82-80 and Western
Pacific 74 (dengue-1 challenge strain) revealed 7 amino acid
substitutions of which 4 were conservative changes. Similarly,
10 amino acid substitutions, of which 4 were conservative
changes, were found between D2-04 and OBS-8041 (dengue-2
challenge strain). It is not clear if these substitutions affected the
level of protection. It is also possible that shuffling altered the
folding of the chimeric envelope proteins.
Virus neutralizing antibodies are of paramount importance
in protection against dengue virus (Kliks et al., 1988) and
epidemiological data suggest that neutralizing antibodies are
sufficient to provide protection against dengue infection. Our
measurement of virus neutralizing antibodies showed that
shuffled vaccines sA and sC produced virus neutralizing
antibodies in macaques to all 4 dengue serotypes, just like
the mixture of 4 parental vaccines did. The antibody titers
were comparable to those reported for a single dose of
recombinant tetravalent live attenuated virus vaccine formu-
lation (PRNT50 of 54, 16, 18 and 126 for dengue-1 to
dengue-4, respectively) in rhesus macaques (Blaney et al.,
2005). These animals were protected against dengue-1, -3
and -4 challenge but not dengue-2. In the study reported
Table 1















1 2 3 4 5 6 7 8
Vector DNA D1 250 4.0
211 + + + + − − − − 4.0 0 0
234 + + + + − − − − 4.0 0 0
D2 212 + + + + + − − − 5.0 4.6 0 0
233 + + + + + − − − 5.0 0 0
213 + + + − + − − − 4.0 0 0
wt Mix D1 252 − − − − − − − − 0.0 1.3 12 14
247 − − + − − − − − 1.0 0 0
249 + − + − + − − − 3.0 33 23
D2 206 + + + + + − − − 5.0 5.3 27 16
225 + − + + + + − − 5.0 39 25
235 + + + + + + − − 6.0 22 32
sA D1 251 + + + + − − − − 4.0 2.3 0 10
240 − − + + − − − − 2.0 0 16
236 − − + − − − − − 1.0 29 51
D2 210 + + + + − − − − 4.0 4.6 14 0
246 + + + + − − − − 4.0 10 0
255 + + + + + + − − 6.0 0 0
sB D1 227 + + + + − − − − 4.0 1.3 34 0
214 − − − − − − − − 0.0 56 13
253 − − − − − − − − 0.0 39 0
D2 219 + + + + − − − − 4.0 5.0 0 0
208 + + + + + + − − 6.0 48 0
239 + + + + + − − − 5.0 0 0
sC D1 205 − − − − − − − − 0.0 2.3 33 36
254 + + + + − − − − 4.0 0 0
230 + − + + − − − − 3.0 0 0
D2 203 + + + + + − − − 5.0 5.0 34 10
217 + + + + + + − − 6.0 20 19
228 + + + − + − 4.0 0 0
sABC D1 231 − − − − − − − − 0.0 0.6 32 0
229 − − + − − − − − 1.0 0 0
258 − − + − − − − − 1.0 42 0
D2 223 + + + + + + − − 6.0 5.0 53 24
201 + + + + + − − − 5.0 22 27
224 + + + + − − − − 4.0 15 13
Presence of virus in the serum of virus challenged animals was determined for 8 days after challenge as described under Materials and methods. Dengue-1 and dengue-
2 viremia were determined by infection of vero and C6/36 cells, respectively. Dengue-1 and dengue-2 challenge virus stocks were produced by propagation in vero and
C6/36 cells, respectively, and using these cells for viremia determination increased assay sensitivity (unpublished). ‘+’ and ‘−’ indicate the presence or absence of virus
in the serum of each animal for each of the days post-challenge. Also shown for reference are the dengue-1 and dengue-2 virus neutralization titers at the time of
challenge (day 0).
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dengue-1 but not dengue-2 in animals immunized with
shuffled vaccine constructs. The same authors (Blaney et al.,
2005) also reported that when dengue-2 neutralizing antibody
titer was raised (PRNT50 = 174) after a second dose of
vaccine, animals were protected from dengue-2 challenge. In
another study using recombinant MVA (modified vaccinia,
Ankara) expressing dengue-2 truncated E (monovalent
vaccine) protein, Men et al. (2000) have reported PRNT50
titers of 70 and higher as being protective. Bray et al. (1996)
have shown that rhesus monkeys vaccinated with a dengue-
2/dengue-4 chimera vaccine (dengue-2 structural genes in an
attenuated dengue-4 background) produced dengue-2 virus
neutralizing antibody titers of about 640 and were protected
from a dengue-2 challenge. Data presented here areconsistent with these studies indicating higher neutralizing
antibody titers are necessary for protection against dengue-2
challenge. However, in a tetravalent dengue vaccine study
using yellow fever virus-dengue chimeras, low antibody
titers of 20–80 were also found protective against dengue-2
challenge (Guirakhoo et al., 2004). It is possible that immune
responses other than antibody response may be contributing
to protection in this case.
It is clear from our study that the animals immunized with
DNA vaccines encoding single chimeric dengue antigens
provided efficient priming against multiple dengue serotypes.
Accumulation of IgM antibody following challenge in some
vaccinated animals may be due to presentation of some epitopes
by the virus not presented by the chimeric antigen. The chimeric
vaccines also provided partial protection against dengue-1
Fig. 5. IgM and IgG antibody responses following virus challenge. Sera obtained on days 0, 3, 6 and 10 (post-challenge) were diluted 1:100 (IgM) or 1:1000 (IgG) and
dengue-1 or dengue-2-specific IgM and IgG were measured by ELISA as described in Materials and methods.
171K. Raviprakash et al. / Virology 353 (2006) 166–173virus challenge. This is the first demonstration that the use of
DNA shuffling technology can produce vaccine candidates
that elicit immune responses against related multiple antigenic
proteins in non-human primates. This is important especially
to dengue vaccinology where epidemiological data mandate
that a vaccine produces protective immune responses to all 4
dengue serotypes. We believe that further investigation to en-
hance immune responses to these and other shuffled vaccine
candidates is warranted.Table 2







Den-1 Den-2 Den-1 Den-2
Vector Den-1 1 (0) 1 (0) 182 (14) 1 (0)
Den-2 1 (0) 1 (0) 1 (0) 56 (14)
wt-mix Den-1 7 (9) 10 (5) 3965 (662) 1178 (616)
Den-2 28 (5) 23 (4) 4140 (724) 2919 (359)
sA Den-1 4 (9) 20 (12) 5339 (389) 2021 (969)
Den-2 5 (3) 1 (0) 2611 (656) 1676 (388)
sB Den-1 42 (6) 5 (3) 5708 (448) 472 (459)
Den-2 3 (15) 2 (2) 706 (588) 1863 (335)
sC Den-1 3 (10) 3 (11) 4369 (884) 1634 (418)
Den-2 8 (9) 11 (3) 2090 (535) 2002 (587)
sABC Den-1 11 (12) 1 (0) 4923 (713) 2560 (458)
Den-2 26 (11) 20 (4) 3474 (767) 3434 (362)
Geometric mean of PRNT50 titers are shown for each group at the time of
challenge as well as 10 days post-challenge. Undetectable titers (<10) were
assigned a value of 1 for purposes of GMT calculation. SE = standard error.Materials and methods
Animals
Rhesus monkeys (Macaca mulatta), of either sex, age 3–
8 years, weighing between 2 and 5 kg, were housed at the Naval
Medical Research Center/Walter Reed Army Institute of
Research animal facility in Silver Spring, MD. The monkeys
were prescreened for the presence of dengue-specific antibody
by enzyme linked immunosorbant assay (ELISA) and the
plaque reduction neutralization test (PRNT). Only those
animals that did not show evidence of previous dengue
exposure were included in the study. Animals were excluded
if the ELISA O.D. exceeded two or more standard deviations at
a 1:100 dilution of their sera when tested against a cocktail of
dengue antigens (PEG precipitated dengue-1, -2, -3 and -4
virions) compared to the O.D. obtained with a negative control
antigen or if the sera (1:10 dilution) exhibited greater than 30%
neutralization of input dengue virus (serotypes 1-4) in a
standard PRNT.
Vaccines
Construction of the parent and shuffled DNA vaccines has
been previously described (Apt et al., 2005). Four parental
DNA constructs (D1, D2, D3 and D4) each expressed prM and
E genes of dengue-1, -2, -3 and -4, respectively. Two shuffled
DNA constructs, sA and sC (clones 6E12-d4 and 2G11-d4,
respectively; Apt et al., 2005), expressed prM and E genes in
which the N-terminal 90% of E gene was shuffled (contained
172 K. Raviprakash et al. / Virology 353 (2006) 166–173portions of sequence representing each of the 4 serotypes). A
third shuffled DNA construct sB (clone 18H6; Apt et al., 2005)
expressed a shuffled truncated E protein. The DNAs were
produced free of endotoxin by Althea Corp., CA.
Immunizations
Groups of 6 animals were immunized by intramuscular
injection of 5 mg empty vector DNA, shuffled vaccine A, B or
C DNA (sA, sB or sC), a mixture of 1.25 mg each of the 4 wild-
type parental DNA (wt-mix) or a mixture of 1.65 mg each of sA,
sB and sC DNA (sABC). Immunizations were repeated at
weeks 4 and 12. Three milliliters of DNA in PBS was
administered at 4 sites (0.65 ml each), one in each of the deltoids
and anterior tibialis muscles. Fig. 2 shows the study design
indicating different vaccinations and challenges.
Antibody analyses
The monkeys were bled at 4-week intervals, and their sera
were tested for dengue serotype-specific antibody by ELISA
and/or PRNT. IgG antibody was detected by ELISA as
previously described (Ansari et al., 1993) except that polyeth-
ylene glycol (PEG) precipitated dengue-1, -2, -3 or -4 virions
were used as the antigen, and a peroxidase-labeled anti-human
IgG was used as the conjugate. A similar procedure with
peroxidase-labeled anti-human IgM was used for IgM determi-
nations. PRNT was performed with vero cells as described
(Russell et al., 1967), using two-fold serial dilutions of serum
samples. A pool of the pre-immune sera of all the animals was
used as the negative control for PRNT. Fifty percent PRNT
titers (PRNT50) were determined by probit analysis using
Minitab software (Minitab Inc, State College, PA).
Virus challenge and viremia
At week 32 (20 weeks after the final dose of vaccine), 3
animals from each vaccine group were challenged with live
dengue-1 or dengue-2 virus. Each monkey was bled prior to
challenge, then inoculated subcutaneously in the upper left arm
with 0.5 ml DMEM containing 105 plaque forming units (PFU)
of dengue-1 (strain Western Pacific 74) or dengue-2 (strain
OBS-8041) virus. The dengue-1 and dengue-2 challenge virus
stocks were produced by propagation in vero or C6/36 cells,
respectively. These virus doses had earlier been determined to
produce uniform viremia of 3–5 days (unpublished). Monkeys
were bled daily for 10 days and again on days 21 and 28 after
challenge. Sera were used to measure viremia and antibody
responses. Viremia was measured by inoculating 25 cm2 flasks
of confluent vero or C6/36 cells in duplicate with 0.2 ml of a
1:10 diluted serum sample. The inoculated cells were incubated
for 10 days at 37 °C in a CO2 incubator. The cells were then
scraped off the flasks, washed with PBS and spotted in duplicate
onto immunofluorescence slides. Dengue-specific antigen was
detected by indirect immunofluorescence using mouse mono-
clonal antibody 7E11 and FITC-conjugated anti-mouse immu-
noglobulin. Monoclonal antibody 7E11 is specific to dengueNS-1 protein and is known to bind NS-1 protein of all 4 dengue
serotypes (unpublished). Slides were examined under a
fluorescent microscope with appropriate positive and negative
controls.
Statistical analyses
Log transformed PRNT-50 titers for each of the 4 dengue
serotypes were analyzed by one-way ANOVA for equality
among different vaccine treatments. Animals that had titers of
zero were assigned a value of 1 for log transformation purpose.
Following one-way ANOVA, comparison of multiple means
was performed using Fisher's LSD test. Because all the animals
in the vector control group had titers of zero indicating no
variability, thus nullifying the assumption of equal variances
among groups, Fisher's LSD test was repeated excluding the
vector control group from analysis. However, both analyses
(with and without control group) produced identical results.
Similarly, for virus challenge data, mean days of viremia for
dengue-1 and dengue-2 were analyzed separately by one-way
ANOVA and Fisher's LSD test.
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